Ubiquitous background standard-of-care therapies neutralize the observable clinical efficacy of next-generation drug candidates.
The widespread real-world use of established standard-of-care treatments creates a high clinical baseline that masks the incremental benefits of next-generation therapies in late-stage combination trials.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
A highly managed background standard-of-care involving stabilizer therapies completely neutralized the observable efficacy of Ionis and AstraZeneca's next-generation silencer.
The outstanding quality of standard background therapies administered to trial patients reduced baseline risks so extensively that pelacarsen's therapeutic effect was entirely masked.
The Phase III trial of eplontersen failed because the widespread baseline use of standard oral stabilizers raised the clinical hurdle so high that no incremental benefit could be demonstrated.
The clinical efficacy of the next-generation gene silencer was completely neutralized when layered on top of existing standard-of-care stabilizer treatments.
The high real-world baseline of existing stabilizer treatments completely obscured any observable clinical benefit of the next-generation gene silencer.
An already-dominant checkpoint-inhibitor standard of care leaves no observable progression-free headroom for the next-generation vaccine added on top of it.
The high potency of the standard-of-care backbone therapy blunted the next-generation candidate's ability to demonstrate a statistically significant benefit.